1.0948
price up icon2.34%   0.0248
 
loading
前日終値:
$1.07
開ける:
$1.08
24時間の取引高:
291.33K
Relative Volume:
0.39
時価総額:
$95.03M
収益:
-
当期純損益:
$-93.61M
株価収益率:
-0.3192
EPS:
-3.43
ネットキャッシュフロー:
$-71.16M
1週間 パフォーマンス:
+0.46%
1か月 パフォーマンス:
-29.35%
6か月 パフォーマンス:
-13.78%
1年 パフォーマンス:
+2.82%
1日の値動き範囲:
Value
$1.05
$1.10
1週間の範囲:
Value
$1.02
$1.13
52週間の値動き範囲:
Value
$0.97
$2.11

Immunic Inc Stock (IMUX) Company Profile

Name
名前
Immunic Inc
Name
セクター
Healthcare (1195)
Name
電話
(332) 255-9818
Name
住所
1200 AVENUE OF THE AMERICAS, NEW YORK
Name
職員
85
Name
Twitter
@ImmunicInc
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
IMUX's Discussions on Twitter

IMUX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IMUX 1.09 95.03M 0 -93.61M -71.16M -3.43
VRTX 450.30 115.43B 10.63B -479.80M -1.35B 13.33
REGN 747.35 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 591.08 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.36 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.34 24.89B 3.30B -501.07M 1.03B 11.54

Immunic Inc Stock (IMUX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2022-10-21 ダウングレード SVB Leerink Outperform → Mkt Perform
2022-09-19 再開されました H.C. Wainwright Buy
2021-04-15 開始されました Aegis Capital Buy
2021-03-24 開始されました JMP Securities Mkt Outperform
2020-10-02 開始されました SVB Leerink Outperform
2020-08-26 開始されました Piper Sandler Overweight
2020-08-07 再開されました ROTH Capital Buy
2020-07-20 開始されました BMO Capital Markets Outperform
2020-06-05 開始されました Wedbush Outperform
2020-05-11 開始されました H.C. Wainwright Buy
2020-03-25 開始されました ROTH Capital Buy
2019-07-11 開始されました Chardan Capital Markets Buy
すべてを表示

Immunic Inc (IMUX) 最新ニュース

pulisher
Nov 16, 2024

Immunic's IMU-856 shows potential in gastrointestinal health trialsICYMI - Proactive Investors UK

Nov 16, 2024
pulisher
Nov 15, 2024

Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Avidity Partners Management LP's Strategic Acquisition in Immuni - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Richard Rudick Spends US$100k On Immunic Stock - Simply Wall St

Nov 15, 2024
pulisher
Nov 15, 2024

Insider Buys Additional US$100k In Immunic Stock - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Janus Henderson Group PLC's Strategic Reduction in Immunic Inc H - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve

Nov 14, 2024
pulisher
Nov 14, 2024

RTW INVESTMENTS, LP Acquires Additional Shares in Immunic Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Immunic announces publication of IMU-856 data - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Director Richard Rudick Acquires 87,300 Shares of Immunic Inc (I - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Immunic director Richard Rudick buys $100,368 in stock By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

Immunic director Richard Rudick buys $100,368 in stock - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Immunic announces publication of IMU-856 Phase 1 trial data in peer-reviewed journal - Proactive Investors USA

Nov 13, 2024
pulisher
Nov 13, 2024

Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet - Proactive Investors USA

Nov 13, 2024
pulisher
Nov 13, 2024

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - PR Newswire

Nov 13, 2024
pulisher
Nov 11, 2024

Immunic, Inc. (NASDAQ:IMUX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 11, 2024
pulisher
Nov 09, 2024

Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges By GuruFocus - Investing.com Canada

Nov 09, 2024
pulisher
Nov 09, 2024

Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic P - GuruFocus.com

Nov 09, 2024
pulisher
Nov 09, 2024

Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Immunic Reports Q3 Earnings and Provides Corporate Update - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

Immunic, Inc. Advances MS Trials Amid Financial Update - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024
pulisher
Nov 07, 2024

Immunic: Q3 Earnings Snapshot - Milford Mirror

Nov 07, 2024
pulisher
Nov 07, 2024

Immunic Inc (IMUX) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Immunic Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz

Nov 07, 2024
pulisher
Nov 07, 2024

Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones - Proactive Investors USA

Nov 07, 2024
pulisher
Nov 07, 2024

Immunic CEO details progress following productive third quarter - Proactive Investors UK

Nov 07, 2024
pulisher
Nov 07, 2024

Immunic's Phase 3 MS Trial Advances Despite Wider Q3 Loss; $59.1M Cash Runway | IMUX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 05, 2024

Immunic's Jessica Breu talks BIO-Europe & MS research advancements - Proactive Investors USA

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group's Strategic Acquisition of Immunic Inc Shares - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - Quantisnow

Nov 04, 2024
pulisher
Nov 01, 2024

Immunic (IMUX) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

EQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Updateboerse.de - boerse.de

Oct 31, 2024
pulisher
Oct 29, 2024

Immunic to Participate in Industry, Scientific and Investor Conferences in November - StockTitan

Oct 29, 2024
pulisher
Oct 29, 2024

Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.20 - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.5% in October - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Reviewing Immunic (NASDAQ:IMUX) & Acasti Pharma (NASDAQ:ACST) - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate - Simply Wall St

Oct 25, 2024
pulisher
Oct 23, 2024

Immunic Therapeutics CMO Dr. Andreas Muehler on Positive Interim Analysis for RMS Trials - Proactive Investors Australia

Oct 23, 2024
pulisher
Oct 23, 2024

Immunic late-stage program for lead asset to proceed as planned - MSN

Oct 23, 2024
pulisher
Oct 22, 2024

Data monitoring committee OKs continuation of phase 3 trial for vidofludimus calcium - Healio

Oct 22, 2024
pulisher
Oct 22, 2024

Interim analysis allows Immunic to stick with phase III MS studies - BioWorld Online

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic stock slips after trial update (IMUX:NASDAQ) - Seeking Alpha

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic Phase 3 MS study advances following positive recommendation from independent committee - Proactive Investors Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic Shares Up 12% on Positive MS Drug Analysis - MarketWatch

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic's phase 3 ENSURE trials for MS drug proceed as planned - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - Marketscreener.com

Oct 22, 2024
pulisher
Oct 22, 2024

EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosisboerse.de - boerse.de

Oct 22, 2024
pulisher
Oct 21, 2024

Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts - Nasdaq

Oct 21, 2024

Immunic Inc (IMUX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):